Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models.

Several COVID-19 vaccines, some more efficacious than others, are now available and deployed, including multiple mRNA- and viral vector-based vaccines. With the focus on creating cost-effective solutions that can reach the low- and medium- income world, GreenLight Biosciences has developed an mRNA vaccine candidate, GLB-COV2-043, encoding for the full-length SARS-CoV-2 Wuhan wild-type spike protein. In pre-clinical studies in mice, GLB-COV2-043 induced robust antigen-specific binding and virus-neutralizing antibody responses targeting homologous and heterologous SARS-CoV-2 variants and a TH1-biased immune response. Boosting mice with monovalent or bivalent mRNA-LNPs provided rapid recall and long-lasting neutralizing antibody titers, an increase in antibody avidity and breadth that was held over time and generation of antigen-specific memory B- and T- cells. In hamsters, vaccination with GLB-COV2-043 led to lower viral loads, reduced incidence of SARS-CoV-2-related microscopic findings in lungs, and protection against weight loss after heterologous challenge with Omicron BA.1 live virus. Altogether, these data indicate that GLB-COV2-043 mRNA-LNP vaccine candidate elicits robust protective humoral and cellular immune responses and establishes our mRNA-LNP platform for subsequent clinical evaluations.

Nanovaccine that activates the NLRP3 inflammasome enhances tumor specific activation of anti-cancer immunity.

Neoantigen cancer vaccines that target tumor specific mutations are emerging as a promising modality for cancer immunotherapy. To date, various approaches have been adopted to enhance efficacy of these therapies, but the low immunogenicity of neoantigens has hindered clinical application. To address this challenge, we developed a polymeric nanovaccine platform that activates the NLRP3 inflammasome, a key immunological signaling pathway in pathogen recognition and clearance. The nanovaccine is comprised of a poly (orthoester) scaffold engrafted with a small-molecule TLR7/8 agonist and an endosomal escape peptide that facilitates lysosomal rupture and NLRP3 inflammasome activation. Upon solvent transfer, the polymer self-assembles with neoantigens to form ∼50 nm nanoparticles that facilitate co-delivery to antigen-presenting cells. This polymeric activator of the inflammasome (PAI) was found to induce potent antigen-specific CD8+ T cell responses characterized by IFN-γ and GranzymeB secretion. Moreover, in combination with immune checkpoint blockade therapy, the nanovaccine stimulated robust anti-tumor immune responses against established tumors in EG.7-OVA, B16·F10, and CT-26 models. Results from our studies indicate that NLRP3 inflammasome activating nanovaccines demonstrate promise for development as a robust platform to enhance immunogenicity of neoantigen therapies.

Subunit Vaccines Using TLR Triagonist Combination Adjuvants Provide Protection Against Coxiella burnetii While Minimizing Reactogenic Responses.

Q fever is caused by the obligate intracellular bacterium, Coxiella burnetii, a designated potential agent of bioterrorism because of its route of transmission, resistance to disinfectants, and low infectious dose. The only vaccine licensed for human use is Q-VAX® (Seqirus, licensed in Australia), a formalin-inactivated whole-cell vaccine, which produces severe local and systemic reactogenic responses in previously sensitized individuals. Accordingly, the U.S. Food and Drug Administration and other regulatory bodies around the world, have been reluctant to approve Q-VAX for widespread use. To obviate these adverse reactions, we prepared recombinant protein subunit vaccine candidates containing purified CBU1910, CBU0307, CBU0545, CBU0612, CBU0891, and CBU1398 proteins and TLR triagonist adjuvants. TLR triagonist adjuvants combine different TLR agonists to enhance immune responses to vaccine antigens. We tested both the protective efficacy and reactogenicity of our vaccine candidates in Hartley guinea pigs using intratracheal infection with live C. burnetii. While all of our candidates showed varying degrees of protection during challenge, local reactogenic responses were significantly reduced for one of our vaccine candidates when compared with a formalin-inactivated whole-cell vaccine. Our findings show that subunit vaccines combined with novel TLR triagonist adjuvants can generate protective immunity to C. burnetii infection while reducing reactogenic responses.

Pathogen-like Nanoassemblies of Covalently Linked TLR Agonists Enhance CD8 and NK Cell-Mediated Antitumor Immunity.

Therapies based on Toll Like Receptor agonists (TLRa) are emerging as a promising modality for cancer immunotherapy to recruit antitumor T-cells in unresponsive immunologically "cold" tumors. Often, combinations of agonists are employed to synergistically enhance efficacy. However, low efficacy and severe toxicities deter these TLR-based therapeutics from further clinical applications. Studies have suggested that the rapid systemic diffusion of agonists to nontarget tissues is the primary cause. To address this challenge, we developed supramolecular nanotherapeutics of covalently linked TLRas for multivalent, synergistic interactions by drawing inspiration from immune recognition of pathogens. This new nanotherapeutic increased stimulation of key pro-inflammatory cytokines and remarkably enhanced CD8 and NK cell-mediated antitumor response while exhibiting ultralow off-target toxicity in an aggressive B16.F10 tumor model. Results from our studies thereby indicate that such supramolecular immune-agonist therapeutics may be further developed as a viable treatment modality for cancer immunotherapy.

From Glucose to Polymers: A Continuous Chemoenzymatic Process.

Efforts to synthesize degradable polymers from renewable resources are deterred by technical and economic challenges; especially, the conversion of natural building blocks into polymerizable monomers is inefficient, requiring multistep synthesis and chromatographic purification. Herein we report a chemoenzymatic process to address these challenges. An enzymatic reaction system was designed that allows for regioselective functional group transformation, efficiently converting glucose into a polymerizable monomer in quantitative yield, thus removing the need for chromatographic purification. With this key success, we further designed a continuous, three-step process, which enabled the synthesis of a sugar polymer, sugar poly(orthoester), directly from glucose in high yield (73 % from glucose). This work may provide a proof-of-concept in developing technically and economically viable approaches to address the many issues associated with current petroleum-based polymers.

Mitigation of Hydrophobicity-Induced Immunotoxicity by Sugar Poly(orthoesters).

Polymeric nanoparticles (NPs) derived from self-assemblies of amphiphilic polymers have demonstrated great potential in clinical applications. However, there are challenges ahead. Notably, immunotoxicity remains a major roadblock that deters the NPs from further applications. Studies suggested that the hydrophobic component is a primary cause, yet biocompatible hydrophobic carbohydrate-based polymers may help mitigate this issue. Herein we design and synthesize novel NP systems having glucose poly(orthoesters) hydrophobic scaffold and polyethylene glycol (PEG) hydrophilic shell. The new NPs exhibited low immunotoxicity both in vitro and in vivo, as measured by the induced cytokine levels. In contrast, when other polymers, such as polylactide (PLA) or polycaprolactone (PCL), were used as the hydrophobic scaffold, the cytokine levels were orders of magnitude higher. Results from our multiple immunological studies indicate that carbohydrate-based polymers can largely mitigate the hydrophobicity-induced immunotoxicity, and thereby they may be good candidate polymers to engineer low immunotoxic biomaterials for various biomedical studies.

Microwave-assisted one-pot conversion of agro-industrial wastes into levulinic acid: An alternate approach.

Brewery liquid waste (BLW), brewery spent grain (BSG), apple pomace solid wastes (APS), apple pomace ultrafiltration sludge (APUS) and starch industry waste (SIW) were evaluated as alternative feedstocks for levulinic acid (LA) production via microwave-assisted acid-catalyzed thermal hydrolysis. LA production of 204, 160, 66, 49 and 12 g/kg was observed for BLW, BSG, APS, APUS, and SIW, respectively, at 140 °C, 40 g/L substrate concentration (SC), 60 min and 2 N HCl (acid concentration). Based on the screening studies, BLW and BSG were selected for optimization studies using response surface methodology. Maximum LA production of 409 and 341 g/kg for BLW and BSG, respectively were obtained at 160 °C, 4.5 M HCl, 85 g/L SC and 27.5 min. Results demonstrated the possibility of using brewery wastes as promising substrates for economical and higher yield production of LA, a renewable platform chemical and versatile precursor for fuels and chemicals.

Hydrolytic pre-treatment methods for enhanced biobutanol production from agro-industrial wastes.

Brewery industry liquid waste (BLW), brewery spent grain (BSG), apple pomace solid wastes (APS), apple pomace ultrafiltration sludge (APUS) and starch industry wastewater (SIW) have been considered as substrates to produce biobutanol. Efficiency of hydrolysis techniques tested to produce fermentable sugars depended on nature of agro-industrial wastes and process conditions. Acid-catalysed hydrolysis of BLW and BSG gave a total reducing sugar yield of 0.433 g/g and 0.468 g/g respectively. Reducing sugar yield from microwave assisted hydrothermal method was 0.404 g/g from APS and 0.631 g/g from APUS, and, 0.359 g/g from microwave assisted acid-catalysed SIW dry mass. Parameter optimization (time, pH and substrate concentration) for acid-catalysed BLW hydrolysate utilization using central composite model technique produced 307.9 g/kg glucose with generation of inhibitors (5-hydroxymethyl furfural (20 g/kg), furfural (1.6 g/kg), levulinic acid (9.3 g/kg) and total phenolic compound (0.567 g/kg)). 10.62 g/L of acetone-butanol-ethanol was produced by subsequent clostridial fermentation of the substrate.

Complete Depolymerization and Repolymerization of a Sugar Poly(orthoester).

The capability of a polymer to depolymerize, regenerating its original monomer for further polymerization, is very attractive in terms of sustainability. Recently discovered sugar poly(orthoesters) are an important class of glycopolymer. The high sensitivity of the backbone orthoester linkage toward acidolysis provides a valuable model to study the depolymerization. Herein, a sugar poly(orthoester) is shown to be completely depolymerized under acidic conditions. Interestingly, instead of the original monomer, the depolymerization gave a stable cyclic product (1,6-anhydro glucopyranose) in most cases, which was kinetically and thermodynamically favored. However, this pathway could be inhibited by chemically deactivating a key intermediate and thus favoring the formation of the original monomer. Efficient repolymerizaton of the regenerated monomer is also demonstrated.

Acid mediated chemical treatment to remove sugar from waste acid stream from nano-crystalline cellulose manufacturing process.

Nano-crystalline cellulose (NCC) is a nano-scale biomaterial derived from highly abundant natural polymer cellulose. It is industrially produced by concentrated acid hydrolysis of cellulosic materials. However, presences of as high as 5-10% of sugar monomers in spent sulphuric acid during the manufacturing process, makes it unsuitable for such recycling or reuse of sulphuric acid. Currently, the industry has been using membrane and ion exchange technology to remove such sugars, however, such technologies cannot achieve the target of 80-90% removal. In the current investigation, thermal treatment and acid mediated thermal treatment have been evaluated for sugar removal from the spent sulphuric acid. Almost complete removal of sugar has been achieved by this approach. Maximum sugar removal efficiency (99.9%) observed during this study was at 120±1°C for 60min using 0.8 ratio (sample: acid) or at 100±1°C for 40min using 1.5 ratio.

Novel spectrophotometric method for detection and estimation of butanol in acetone-butanol-ethanol fermenter.

A new, simple, rapid and selective spectrophotometric method has been developed for detection and estimation of butanol in fermentation broth. The red colored compound, produced during reduction of diquat-dibromide-monohydrate with 2-mercaptoethanol in aqueous solution at high pH (>13), becomes purple on phase transfer to butanol and gives distinct absorption at λ520nm. Estimation of butanol in the fermentation broth has been performed by salting out extraction (SOE) using saturated K3PO4 solution at high pH (>13) followed by absorbance measurement using diquat reagent. Compatibility and optimization of diquat reagent concentration for detection and estimation of butanol concentration in the fermentation broth range was verified by central composite design. A standard curve was constructed to estimate butanol in acetone-ethanol-butanol (ABE) mixture under optimized conditions. The spectrophotometric results for butanol estimation, was found to have 87.5% concordance with the data from gas chromatographic analysis.